Qubad M, Bittner R
Ther Adv Psychopharmacol. 2023; 13:20451253231158152.
PMID: 36994117
PMC: 10041648.
DOI: 10.1177/20451253231158152.
Kikuchi Y, Kanbayashi T, Shimizu T
Psychiatry Investig. 2019; 16(4):279-284.
PMID: 30947495
PMC: 6504775.
DOI: 10.30773/pi.2018.12.16.
Diaz F, Josiassen R, De Leon J
J Clin Psychopharmacol. 2018; 38(5):442-446.
PMID: 30106876
PMC: 6113094.
DOI: 10.1097/JCP.0000000000000926.
Toth K, Csukly G, Sirok D, Belic A, Kiss A, Hafra E
Int J Neuropsychopharmacol. 2017; 20(7):529-537.
PMID: 28340122
PMC: 5492788.
DOI: 10.1093/ijnp/pyx019.
Olsson E, Edman G, Bertilsson L, Hukic D, Lavebratt C, Eriksson S
Prim Care Companion CNS Disord. 2015; 17(1).
PMID: 26137357
PMC: 4468884.
DOI: 10.4088/PCC.14m01704.
Effect of smoking on the pharmacokinetics of inhaled loxapine.
Takahashi L, Huie K, Spyker D, Fishman R, Cassella J
Ther Drug Monit. 2014; 36(5):618-23.
PMID: 24937085
PMC: 4218760.
DOI: 10.1097/FTD.0000000000000048.
Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine.
Tsuda Y, Saruwatari J, Yasui-Furukori N
BMJ Open. 2014; 4(3):e004216.
PMID: 24595134
PMC: 3948577.
DOI: 10.1136/bmjopen-2013-004216.
Role of Statistical Random-Effects Linear Models in Personalized Medicine.
Diaz F, Yeh H, De Leon J
Curr Pharmacogenomics Person Med. 2013; 10(1):22-32.
PMID: 23467392
PMC: 3580802.
DOI: 10.2174/1875692111201010022.
Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.
Mauri M, Volonteri L, Colasanti A, Fiorentini A, De Gaspari I, Bareggi S
Clin Pharmacokinet. 2007; 46(5):359-88.
PMID: 17465637
DOI: 10.2165/00003088-200746050-00001.
Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia.
Tang Y, Mao P, Li F, Li W, Chen Q, Jiang F
Br J Clin Pharmacol. 2007; 64(1):49-56.
PMID: 17298477
PMC: 2000616.
DOI: 10.1111/j.1365-2125.2007.02852.x.
Sex and age differences in the pharmacokinetics of alosetron.
Koch K, Palmer J, Noordin N, TOMLINSON J, Baidoo C
Br J Clin Pharmacol. 2002; 53(3):238-42.
PMID: 11874386
PMC: 1874312.
DOI: 10.1046/j.0306-5251.2001.01565.x.
Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.
DESAI H, Seabolt J, Jann M
CNS Drugs. 2001; 15(6):469-94.
PMID: 11524025
DOI: 10.2165/00023210-200115060-00005.
Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.
Fitton A, Benfield P
Pharmacoeconomics. 1993; 4(2):131-56.
PMID: 10146973
DOI: 10.2165/00019053-199304020-00007.
New atypical antipsychotics. Experience and utility in the elderly.
Sweet R, Pollock B
Drugs Aging. 1998; 12(2):115-27.
PMID: 9509290
DOI: 10.2165/00002512-199812020-00004.
Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes.
Fleischhacker W, Hummer M
Drugs. 1997; 53(6):915-29.
PMID: 9179524
DOI: 10.2165/00003495-199753060-00002.
Clozapine plasma level monitoring: current status.
Cooper T
Psychiatr Q. 1996; 67(4):297-311.
PMID: 8938830
DOI: 10.1007/BF02326373.
Effect of treatment duration on plasma levels of clozapine and N-desmethylclozapine in men and women.
Fabrazzo M, Esposito G, Fusco R, Maj M
Psychopharmacology (Berl). 1996; 124(1-2):197-200.
PMID: 8935816
DOI: 10.1007/BF02245621.
Pharmacokinetics and pharmacodynamics of clozapine.
Jann M, Grimsley S, Gray E, Chang W
Clin Pharmacokinet. 1993; 24(2):161-76.
PMID: 8453823
DOI: 10.2165/00003088-199324020-00005.
EEG alterations in patients treated with clozapine in relation to plasma levels.
Haring C, Neudorfer C, Schwitzer J, Hummer M, Saria A, Hinterhuber H
Psychopharmacology (Berl). 1994; 114(1):97-100.
PMID: 7846212
DOI: 10.1007/BF02245449.
Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study.
Olesen O, Thomsen K, JENSEN P, Wulff C, Rasmussen N, Refshammer C
Psychopharmacology (Berl). 1995; 117(3):371-8.
PMID: 7770613
DOI: 10.1007/BF02246112.